Basic Information
| LncRNA/CircRNA Name | FOXC2-AS1 |
| Synonyms | NA |
| Region | GRCh38_16:86565145-86567761 |
| Ensemble | ENSG00000260944 |
| Refseq | NR_125795 |
Classification Information
| Regulatory Mechanism | Biological Function | Clinical Application | |||
|---|---|---|---|---|---|
| TF | Immune | Survival | |||
| Enhancer | Apoptosis | apoptosis | Drug | ||
| Variant | Cell Growth | Circulating | |||
| MiRNA | EMT | Metastasis | |||
| Methylation | Coding Ability | Recurrence |
Cancer&Entry Information
| Cancer Name | non small cell lung cancer |
| ICD-0-3 | C34 |
| Methods | qPCR, Western blot, RIP |
| Sample | NSCLC cell lines (SK-MES-1, A549, H460, SPCA1), The human bronchial epithelial cell (NHBE), NSCLC tissue, normal tissue, NSCLC tissue, normal tissue |
| Expression Pattern | up-regulated |
| Function Description | In the functional experiments, the knockdown of FOXC2-AS1 dramatically suppressed the NSCLC cells` (A549, H460) proliferation, accelerated the apoptosis and induced the cycle arrest at G0/G1 phase. Mechanistic experiments revealed that FOXC2-AS1 repressed the p15 expression via recruiting the polycomb repressive complex 2 (PRC2) to the promoter of p15. The interaction within FOXC2-AS1 and p15 was validated using the rescue experiments. FOXC2-AS1 could aggravate NSCLC oncogenesis through repressing p15 expression via interacting EZH2, which provide new idea for the NSCLC therapeutic strategy. |
| Pubmed ID | 31396359 |
| Year | 2019 |
| Title | LncRNA FOXC2 Antisense Transcript Accelerates Non-Small-Cell Lung Cancer Tumorigenesis via Silencing p15 |
External Links
| Links for FOXC2-AS1 | GenBank HGNC NONCODE |
| Links for non small cell lung cancer | OMIM COSMIC |